Your browser doesn't support javascript.
loading
ERICH3: vesicular association and antidepressant treatment response.
Liu, Duan; Zhuang, Yongxian; Zhang, Lingxin; Gao, Huanyao; Neavin, Drew; Carrillo-Roa, Tania; Wang, Yani; Yu, Jia; Qin, Sisi; Kim, Daniel C; Liu, Erica; Nguyen, Thanh Thanh Le; Biernacka, Joanna M; Kaddurah-Daouk, Rima; Dunlop, Boadie W; Craighead, W Edward; Mayberg, Helen S; Binder, Elisabeth B; Frye, Mark A; Wang, Liewei; Weinshilboum, Richard M.
Afiliação
  • Liu D; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Zhuang Y; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Zhang L; Rubedo Life Sciences, Sunnyvale, CA, USA.
  • Gao H; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Neavin D; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Carrillo-Roa T; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Wang Y; Centre for Cellular Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia.
  • Yu J; Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
  • Qin S; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Kim DC; Xi'an No.1 Hospital, the First Affiliated Hospital of Northwest University, Xi'an, Shaanxi, China.
  • Liu E; Shaanxi Institute of Ophthalmology, Shaanxi Key Laboratory of Ophthalmology, Shaanxi Clinical Research Center for Ophthalmology Diseases, Xi'an, Shaanxi, China.
  • Nguyen TTL; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Biernacka JM; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Kaddurah-Daouk R; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Dunlop BW; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Craighead WE; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
  • Mayberg HS; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
  • Binder EB; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Frye MA; Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.
  • Wang L; Department of Medicine, Duke University, Durham, NC, USA.
  • Weinshilboum RM; Duke Institute for Brain Sciences, Duke University, Durham, NC, USA.
Mol Psychiatry ; 26(6): 2415-2428, 2021 06.
Article em En | MEDLINE | ID: mdl-33230203
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior Tipo de estudo: Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior Tipo de estudo: Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article